Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Research from Mayo Clinic yields new findings on bladder cancer
September 2nd, 2008
According to a study from the United States, "To assess the reproducibility of the UroVysion fluorescence in situ hybridization (FISH) bladder cancer detection assay. Thirteen specimens (2 negative, 3 low-level positive [1-10% abnormal cells], 5 mid-level positive [11-75%], and 3 high-level positive [> 75%]) were analyzed by 7 cytotechnologists." "Each cytotechnologist rendered an overall diagnosis of positive or negative and determined the percentage of abnormal urothelial cells for all positive specimens. The interobserver reproducibility of the assay was 100% for mid-level and high-level positive specimens, 93% for negative specimens, and 78% for low-level...
Source: Cancer Weekly (2008-09-02)
|
